Company Filing History:
Years Active: 2012-2015
Title: Almuth Marx: Innovator in Breast Cancer Prognosis
Introduction
Almuth Marx is a notable inventor based in Nuremberg, Germany. He has made significant contributions to the field of breast cancer research, particularly in the development of methods for prognosis and treatment response prediction. With a total of 2 patents, his work is paving the way for advancements in cancer diagnostics.
Latest Patents
Almuth Marx's latest patents include innovative methods for the prognosis of breast cancer. The first patent focuses on modified and genomic sequences, as well as oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA. This invention aims to predict disease-free survival and response to endocrine treatment in subjects with cell proliferative disorders of breast tissues. The second patent addresses the risk of relapse of breast cancer following tamoxifen adjuvant therapy, utilizing similar genomic techniques to enhance treatment outcomes.
Career Highlights
Almuth Marx is currently associated with Epigenomics AG, where he continues to advance his research in cancer diagnostics. His work is characterized by a strong emphasis on genomic analysis and its application in clinical settings.
Collaborations
Throughout his career, Almuth has collaborated with esteemed colleagues such as John Foekens and Nadia Harbeck, who contribute to the multidisciplinary approach in his research endeavors.
Conclusion
Almuth Marx's innovative work in breast cancer prognosis exemplifies the critical intersection of technology and medicine. His contributions are vital for improving patient outcomes and advancing cancer research.